7IM has reported a 21% fall in platform outflows alongside record net sales of £540m in the second quarter of the year. The firm said gross sales exceeded £1bn for only the second time, helping push ...

If you’re looking for the best camera phones available for less than Rs 66,000, we’ve found the best deal. Just in time for Diwali 2025, the Vivo X200’s top variant with 16GB RAM and 512GB storage is ...

[NEW YORK] The US banking system’s reserves, a key factor in the US Federal Reserve’s decision to keep shrinking its balance sheet, tumbled for the second straight week, further below US$3 trillion ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The so-called Delete Request and Opt-out Platform, known as DROP, will go live Jan 1, 2026. The system has been in the works since September 2023, when lawmakers mandated its creation by passing the ...

Chinese wind turbine manufacturer Ming Yang Smart Energy is reportedly planning to debut a 50-megawatt (MW), two-headed floating wind turbine that could upend the offshore wind industry because of its ...

HONG KONG: Asian stocks sank on Tuesday (Oct 14) on fresh trade war worries after China imposed curbs on US units of a Korean shipbuilder, dealing a blow to hopes that a flare-up at the weekend had ...

Netflix shares slumped almost 7% after missing its Q3 earnings following an unplanned $619m (£464.5m) tax bill in Brazil. Revenues were up 17% to $11.5bn (£8.6bn) as expected, with the company ...

Late last year, following four years of construction, Shell 011 Company's recordsetting "Auger" tension leg platform (TLP) was towed out to its new home, some 255 miles southeast of Houston, Texas, in ...

Want to build a website with minimal cost and effort? The best website builders we've tested include useful tools for quickly creating attractive, well-designed pages for blogs, online businesses, and ...

Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion. As we reported ...